Cantor Fitzgerald reiterated their hold rating on shares of Teladoc Health (NYSE:TDOC) in a research report released on Wednesday morning, Marketbeat reports. The firm currently has a $70.00 target price on the health services provider’s stock, down from their previous target price of $83.00.

“. We reiterate our Neutral rating on TDOC shares and lower our 12-month price target to $70 from $83. After the close on Wednesday, Feb. 27, TDOC reported 4Q18 results. Revenue and adjusted EBITDA were slightly above our estimate and FactSet consensus. TDOC provided its initial 2019 guidance, which was below our estimates and consensus. We continue to believe that TDOC is positioned to benefit from increasing virtual health adoption. However, the shares’ current valuation, relative to our revised price target, keeps us on the sidelines.”,” Cantor Fitzgerald’s analyst wrote.

A number of other brokerages also recently issued reports on TDOC. Jefferies Financial Group set a $95.00 price objective on Teladoc Health and gave the company a buy rating in a research note on Friday, November 2nd. Chardan Capital upped their price objective on Teladoc Health from $98.00 to $100.00 and gave the company a buy rating in a research note on Friday, November 2nd. Zacks Investment Research upgraded Teladoc Health from a sell rating to a hold rating in a research note on Monday, February 18th. TheStreet upgraded Teladoc Health from a d+ rating to a c rating in a research note on Wednesday, February 20th. Finally, Berenberg Bank assumed coverage on Teladoc Health in a research note on Thursday, January 31st. They issued a buy rating and a $80.00 price objective for the company. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $83.16.

NYSE:TDOC traded up $3.19 during trading on Wednesday, reaching $67.55. The company’s stock had a trading volume of 1,831,655 shares, compared to its average volume of 910,280. The company has a market capitalization of $4.85 billion, a PE ratio of -46.91 and a beta of 1.47. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. Teladoc Health has a 12 month low of $38.05 and a 12 month high of $89.05.

In other news, CEO Jason N. Gorevic sold 30,000 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $69.68, for a total transaction of $2,090,400.00. Following the transaction, the chief executive officer now owns 631,875 shares of the company’s stock, valued at approximately $44,029,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew Turitz sold 8,202 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $64.14, for a total value of $526,076.28. Following the transaction, the senior vice president now directly owns 9,378 shares in the company, valued at approximately $601,504.92. The disclosure for this sale can be found here. Insiders have sold a total of 130,745 shares of company stock worth $7,911,090 in the last ninety days. Insiders own 3.95% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of TDOC. Enlightenment Research LLC purchased a new position in shares of Teladoc Health during the 4th quarter valued at $25,000. Nikko Asset Management Americas Inc. purchased a new stake in Teladoc Health during the 4th quarter worth about $25,000. Ffcm LLC purchased a new stake in Teladoc Health during the 4th quarter worth about $32,000. Parkside Financial Bank & Trust lifted its holdings in Teladoc Health by 1,455.0% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,244 shares of the health services provider’s stock worth $62,000 after purchasing an additional 1,164 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in Teladoc Health during the 4th quarter worth about $83,000.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Penny Stocks

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.